Interspecies Prediction of Human Drug Clearance Based on Scaling Data from One or Two Animal Species

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Drug Metabolism And Disposition

• Publication date

  2007-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.107.016188PMID 17646280
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RESPONSE TO COMMENTS ON “A MATHEMATICAL DESCRIPTION OF THE FUNCTIONALITY OF CORRECTION FACTORS USED IN ALLOMETRY FOR PREDICTING HUMAN DRUG CLEARANCE”

  2006influential reference
• Prediction of human drug clearance from animal data: application of the rule of exponents and 'fu Corrected Intercept Method' (FCIM).

  2006influential reference
• A MATHEMATICAL DESCRIPTION OF THE FUNCTIONALITY OF CORRECTION FACTORS USED IN ALLOMETRY FOR PREDICTING HUMAN DRUG CLEARANCE

  2005influential reference
• Interspecies scaling of biliary excreted drugs: a comparison of several methods.

  2005cited by this paper
• ACCURACY OF ALLOMETRICALLY PREDICTED PHARMACOKINETIC PARAMETERS IN HUMANS: ROLE OF SPECIES SELECTION

  2005influential reference
• Allometric scaling of mammalian metabolism

  2005influential reference
• The correction factors do help in improving the prediction of human clearance from animal data.

  2005cited by this paper
• Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.

  2005cited by this paper
• A NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING

  2005influential reference
• A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans.

  2004cited by this paper
• A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.

  2004cited by this paper
• Interspecies Scaling of Bosentan, A New Endothelin Receptor Antagonist and Integration of in Vitro Data into Allometric Scaling

  2004cited by this paper
• Allometric Pharmacokinetic Scaling: Towards the Prediction of Human Oral Pharmacokinetics

  2000cited by this paper
• Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.

  2000influential reference
• Correlation of Plasma Clearance of 54 Extensively Metabolized Drugs Between Humans and Rats: Mean Allometric Coefficient of 0.66

  1998influential reference
• The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

  1997influential reference
• Interspecies scaling: predicting clearance of drugs in humans. Three different approaches.

  1996cited by this paper
• Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance.

  1996influential reference
• Man versus beast: pharmacokinetic scaling in mammals.

  1986cited by this paper
• Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics

  1982influential reference

• Model-Informed Prediction of Human Pharmacokinetics and First-in-Human Dose Selection of J2H-1702, a Novel 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor for Metabolic-Associated Steatohepatitis.

  2026cites this paper
• Delivery of Islatravir via High Drug‐Load, Long‐acting Microarray Patches for the Prevention or Treatment of Human Immunodeficiency Virus

  2025cites this paper
• What Do Oral Drugs Really Look Like? Dose Regimen, Pharmacokinetics, and Safety of Recently Approved Small-Molecule Oral Drugs

  2025cites this paper
• Large-Scale Compartmental Model-Based Study of Preclinical Pharmacokinetic Data and Its Impact on Compound Triaging in Drug Discovery.

  2025cites this paper
• Beyond-Rule-of-Five Compounds Are Not Different: In Vitro–In Vivo Extrapolation of Female CD-1 Mouse Clearance Based on Merck Healthcare KGaA Compound Set

  2025cites this paper
• A Bottom-up Approach for Mutant and Wild Type Collies Using Physiologically Based Pharmacokinetic (PBPK) Modeling: A Case Study Using Loperamide

  2025influential citation
• Assessing hepatic impairment with biomarker-informed physiologically based pharmacokinetic modeling: Strengths and limitations of the endogenous biomarker Coproporphyrin I.

  2025cites this paper
• Prediction of SPT-07A Pharmacokinetics in Rats, Dogs, and Humans Using a Physiologically-Based Pharmacokinetic Model and In Vitro Data

  2024cites this paper
• SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy

  2024cites this paper
• Prediction of Human Pharmacokinetics of E0703, a Novel Radioprotective Agent, Using Physiologically Based Pharmacokinetic Modeling and an Interspecies Extrapolation Approach

  2024influential citation
• Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials

  2024cites this paper
• Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation

  2024cites this paper
• Applications of the Cholesterol Metabolite, 4β-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK Framework

  2024cites this paper
• A cross-species assessment of in silico prediction methods of steady-state volume of distribution using Simcyp Simulators.

  2024cites this paper
• Prediction of Human Pharmacokinetics of Phosphorodiamidate Morpholino Oligonucleotides in Duchenne Muscular Dystrophy Patients Using Viltolarsen

  2023cites this paper
• Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug–Drug Interaction between Rivaroxaban and Carbamazepine in Humans

  2023cites this paper
• Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics

  2022cites this paper
• Current Approaches for Predicting Human PK for Small Molecule Development Candidates: Findings from the IQ Human PK Prediction Working Group Survey

  2022cites this paper
• Drug Disposition Protein Quantification in Matched Human Jejunum and Liver From Donors With Obesity

  2022cites this paper
• Physiologically Based Pharmacokinetic Modeling for Quantitative Prediction of Exposure to a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Substrate of Cytochrome P450 and Aldehyde Oxidase, Using Chimeric Mice With Humanized Liver

  2022cites this paper
• Approaches for estimating the clinical starting dose of new dosage forms: An example of a long-acting injectable formulation of finasteride.

  2022cites this paper
• Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans

  2022cites this paper
• Utility of preclinical species for uncertainty assessment and correction of prediction of human volume of distribution using the Rodgers-Lukacova model

  2022cites this paper
• Characterisation of intravenous pharmacokinetics in Göttingen minipig and clearance prediction using established in vitro to in vivo extrapolation methodologies

  2022influential citation
• Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate

  2021cites this paper
• Translational Pharmacokinetic–Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose

  2021cites this paper
• Next generation risk assessment of human exposure to anti-androgens using newly defined comparator compound values.

  2021cites this paper
• Prediction of a clinically effective dose of THY1773, a novel V 1B receptor antagonist, based on preclinical data

  2021cites this paper
• Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes

  2021cites this paper
• Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance

  2021cites this paper
• Comparison of Various Approaches to Translate Non-Linear Pharmacokinetics of Monoclonal Antibodies from Cynomolgus Monkey to Human

  2021cites this paper
• Metabolism and pharmacokinetics characterization of metarrestin in multiple species

  2020cites this paper
• Innovative approaches in CNS clinical drug development: Quantitative systems pharmacology.

  2020cites this paper
• Prediction of volume of distribution in humans: analysis of eight methods and their application in drug discovery

  2020cites this paper
• Special Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde s

  2020cites this paper
• The role of quantitative modeling and simulation in translational science

  2020cites this paper
• Application of an Inter-Species Extrapolation Method for the Prediction of Drug Interactions between Propolis and Duloxetine in Humans

  2020cites this paper
• Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.

  2020cites this paper
• A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release.

  2020cites this paper
• Mechanisms of Herb-Drug Interactions Involving Cinnamon and Cytochrome P450 2A6: Focus on Time-dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde

  2020cites this paper
• Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants

  2020cites this paper
• Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221

  2019cites this paper
• Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling

  2019cites this paper
• Identification and human exposure prediction of two aldehyde oxidase-mediated metabolites of a methylquinoline-containing drug candidate

  2019influential citation
• Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver

  2019cites this paper
• Utility of Chimeric Mice with Humanized Liver for Predicting Human Pharmacokinetics in Drug Discovery: Comparison with in Vitro-in Vivo Extrapolation and Allometric Scaling.

  2019cites this paper
• Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery

  2019cites this paper
• Porcine Prediction of Pharmacokinetic Parameters in People: A Pig in a Poke?

  2018cites this paper
• A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry

  2018cites this paper
• Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach

  2018cites this paper
• Polymerization Induced Self-Assembly of a Site-Specific Interferon α-Block Copolymer Conjugate into Micelles with Remarkably Enhanced Pharmacology.

  2018cites this paper
• Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs.

  2018cites this paper
• Strategy for Extending Half-life in Drug Design and Its Significance.

  2018cites this paper
• Comparison of methods for the prediction of human clearance from hepatocyte intrinsic clearance for a set of reference compounds and an external evaluation set

  2017influential citation
• A comparative evaluation of models to predict human intestinal metabolism from nonclinical data

  2017cites this paper
• Translational Model‐Based Strategy to Guide the Choice of Clinical Doses for Antibody–Drug Conjugates

  2017cites this paper
• Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes.

  2017cites this paper
• Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Interspecies Scaling of Recombinant Human Coagulation Factor XaI16L.

  2017cites this paper
• Mechanistic investigations into the species differences in pinometostat clearance: impact of binding to alpha-1-acid glycoprotein and permeability-limited hepatic uptake

  2017cites this paper
• Upcyte Human Hepatocytes: a Potent In Vitro Tool for the Prediction of Hepatic Clearance of Metabolically Stable Compounds

  2016cites this paper
• Aldehyde Oxidase Drug Metabolism: Evaluation of Drug Interaction Potential and Allometric Scaling Methods to Predict Human Pharmacokinetics

  2016cites this paper
• A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose

  2016cites this paper
• Prediction of Metabolic Clearance for Low-Turnover Compounds Using Plated Hepatocytes with Enzyme Activity Correction

  2016cites this paper
• A unified strategy in selection of the best allometric scaling methods to predict human clearance based on drug disposition pathway

  2016cites this paper
• Validation of Early Human Dose Prediction: A Key Metric for Compound Progression in Drug Discovery.

  2016cites this paper
• Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.

  2016cites this paper
• Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug

  2016cites this paper
• Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels

  2016cites this paper
• Prediction of Plasma Concentration-time Profiles of Drugs in Humans from Animals Following Oral Administration: An Allometric Approach.

  2016cites this paper
• In-Silico Methods for De-Risking the Clinical Development of Subcutaneously Administered Therapeutic Macromolecules

  2016cites this paper
• Comparative Study of First-in-Human Dose Estimation Approaches using Pharmacometrics

  2016cites this paper
• Predictability of plasma concentration–time curves in humans using single-species allometric scaling of chimeric mice with humanized liver

  2015cites this paper
• Towards a non-animal risk assessment for anti-androgenic effects in humans.

  2015cites this paper
• Interspecies allometric meta-analysis of the comparative pharmacokinetics of 85 drugs across veterinary and laboratory animal species.

  2015cites this paper
• Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.

  2015cites this paper
• Microsoft Word-64262667-file00

  2015cites this paper
• Absorción gastrointestinal de la nevirapina en la rata y potenciales interacciones farmacocinéticas con fármacos antidepresivos

  2015cites this paper
• Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse Model

  2015cites this paper
• Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™.

  2015cites this paper
• Drug Development Strategies for Therapeutic Biologics: Industry Perspectives

  2015cites this paper
• Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model

  2015cites this paper
• The Effects of Ethanol and Nicotine on Hepatic and Brain CYP2 Family Enzymes in African Green Monkeys

  2014cites this paper
• Utility of cryopreserved hepatocytes suspended in serum to predict hepatic clearance in dogs and monkeys.

  2014cites this paper
• Evaluation of the Allometric Exponents in Prediction of Human Drug Clearance

  2014cites this paper
• Interspecies Pharmacokinetics. 1. Allometric Scaling of Pharmacokinetic Parameters (a Review)

  2014cites this paper
• Integrated Assessment of Drug Clearance and Cross‐Species Scalability

  2014cites this paper
• Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using Preclinical In Vitro and in Vivo Data

  2014cites this paper
• Human pharmacokinetics of xanthohumol, an antihyperglycemic flavonoid from hops.

  2014cites this paper
• Metabolic scaling in animals: methods, empirical results, and theoretical explanations.

  2014cites this paper
• FDA Bioequivalence Standards

  2014cites this paper
• Preclinical Safety Testing

  2013cites this paper
• Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics.

  2013cites this paper
• The volume of distribution is an indicator of poor in vitro–in vivo extrapolation of clearance for acidic drugs in the rat

  2013influential citation
• Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM)

  2013cites this paper
• Application of Hybrid Approach Based on Empirical and Physiological Concept for Predicting Pharmacokinetics in Humans—Usefulness of Exponent on Prospective Evaluation of Predictability

  2013cites this paper
• Pharmacokinetics and Toxicokinetics

  2013cites this paper
• Quantitative Structure − Activity Relationship Models of Clinical Pharmacokinetics : Clearance and Volume of Distribution

  2013cites this paper
• Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development

  2013influential citation
• Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance

  2013cites this paper
• Chapter 3 – Pharmacokinetics and Toxicokinetics

  2013cites this paper